CRVO
CervoMed Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.56
+0.79%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 322.6K | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | 322.6K | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 21.3M | 21.8M | 18.8M | 8.4M | 1.3M |
| SG&A Expense | 10.2M | 10.5M | 9.2M | 6.5M | 2.1M |
| General & Admin Expense | 10.2M | 10.5M | 9.2M | 6.5M | 2.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (8.7K) | (4.0M) | (9.7M) | (7.1M) | — |
| Total Operating Expenses | 31.5M | 28.3M | 18.2M | 7.8M | 3.5M |
| Cost and Expenses | 31.5M | 28.3M | 18.2M | 7.8M | 3.5M |
| Operating Income (EBIT) | (31.2M) | (28.3M) | (18.2M) | (7.8M) | (3.5M) |
| Non-Operating | |||||
| Interest Income | 812.0K | 1.3M | 1.9M | 219.4K | 62.2K |
| Interest Expense | — | — | — | — | 587.00 |
| Net Interest Income | 812.0K | 1.3M | 1.9M | 219.4K | 61.6K |
| Other Non-Op Income/Expense | 815.1K | 1.3M | 1.9M | 5.6M | (2.3M) |
| Non-Operating Income (excl Interest) | (815.1K) | (1.3M) | (1.9M) | (5.6M) | 2.3M |
| EBT (Pre-Tax Income) | (30.3M) | (27.0M) | (16.3M) | (2.2M) | (5.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (30.3M) | (27.0M) | (16.3M) | (2.2M) | (5.8M) |
| Earnings from Cont. Ops | (30.3M) | (27.0M) | (16.3M) | (2.2M) | (5.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (30.3M) | (27.0M) | (16.3M) | (2.2M) | (5.8M) |
| Per Share | |||||
| Basic EPS | ($3.21) | ($2.98) | ($2.02) | ($0.82) | ($11.20) |
| Diluted EPS | ($3.21) | ($2.98) | ($2.02) | ($0.82) | ($11.20) |
| Revenue Per Share | $0.03 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 10.2M | 9.0M | 8.1M | 2.7M | 518139 |
| Diluted Shares Outstanding | 10.2M | 9.0M | 8.1M | 2.7M | 518139 |
| Profitability Metrics | |||||
| EBITDA | (30.3M) | (27.0M) | (16.3M) | (2.2M) | (5.8M) |
| D&A | — | — | — | — | — |
| EBIT | (30.3M) | (27.0M) | (16.3M) | (2.2M) | (5.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026